Neurowyzr’s Post

There shouldn't be people with epilepsy who still struggle with uncontrolled seizures. About 1 million live with refractory seizures that don’t respond to current treatments. It’s eye-opening to see that despite advances in medicine, 85% of these patients don’t find relief from existing therapies. The focus on new solutions, like innovative drug treatments and advanced medical technologies such as Anaphylm (epinephrine) Sublingual Film, feels so important. As someone who values progress in medical science, I’m hopeful that these new approaches will make a real difference in the lives of those battling epilepsy. #Epilepsy #Medical #seizures #innovation #505B2

Traumatic Brain Injury (TBI) presents a significant challenge in healthcare, being the leading cause of death and disability in individuals under 45. The Brain Injury Research Foundation (The BIRF)is addressing this critical issue head-on. Despite numerous clinical trials, effective TBI treatments remain elusive. The BIRF is dedicated to changing this narrative by decreasing costs and enhancing the effectiveness of TBI drug launches. Their approach focuses on innovative public-private partnerships, crucial for developing new drug treatments. The BIRF is advocating for a unique three-stage model to foster collaboration between research institutions and industry leaders. This initiative, including programs like SynapFx and PRECEPT, aims to accelerate the discovery of novel neurotherapeutics and reshape the future of TBI care. #TBIResearch #BrainHealth #TBI #BIRF

🧠 Abbott starts clinical trial of DBS system for treatment-resistant depression The US Food and Drug Administration (FDA) awarded the company breakthrough device designation to explore the use of deep brain stimulation for TRD in July 2022. TRANSCEND is intended to assess the potential of DBS to enhance treatment options for individuals with life-threatening or severely debilitating conditions. DBS is a personalised, adjustable therapy that functions similarly to a pacemaker, delivering small, precise electrical pulses to targeted brain regions to alleviate symptoms. Read more online: https://lnkd.in/eGB2zGv6 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing

Recent medical research has uncovered a troubling connection between the widely used contraceptive injection, Depo-Provera, and the development of brain tumors known as meningiomas. If you have been using the Depo shot and have developed neurological symptoms or undergone life-changing medical procedures, you may be entitled to compensation. Learn More: https://lnkd.in/gHYR77gX Fill our out Depo-Provera questionnaire to see if you are entitled to compensation: https://lnkd.in/gPRs279v . . . #DepoProvera #Meningioma #ContraceptiveAwareness #CompensationClaims #PatientAdvocacy #personalinjury #injurylawyer #injuryattorney #classaction #personalinjurylawyer #personalinjuryattorney

Metabolic screening for CTX should be performed in patients with ASD when accompanied by diarrhea, intellectual disability, juvenile cataract, and/or neurological involvement. Early recognition allows for earlier initiation of specific treatment and will improve clinical outcome. #CTX #CTXAlliance #ULF #CerebrotendinousXanthomatosis #Leukodystrophy #RareDisease

We are excited to update that Clexio has initiated a Phase 2 Proof of Concept study, to assess the efficacy and safety of CLE-400 topical gel for the treatment of chronic pruritus in adults with Notalgia Paresthetica. The study is a randomized, double-blind, vehicle controlled multicenter study enrolling in the US.   Notalgia Paresthetica is a type of sensory neuropathy responsible for chronic itch in the upper back. Many who suffer from this condition find it affects their days and nights, their everyday functions, and may impact their quality of life and well-being. To-date, there are no approved treatments for this condition. CLE-400 is a topical formulation containing a potent α2-adrenergic agonist molecule that is both a non-opioid and a non-steroid.   For more information on CLE-400: https://lnkd.in/dqsbbiEJ #nervepain #notalgiaparesthetica #clexio #clinicaltrials  

At Home Therapy Devices to Improve Gut and Brain Health - launching soon on IndieGoGo! The Kineon CALM+ and HEAL+ is a complementary system that stands apart with its non-pharmaceutical, non-invasive approach to improving gut and brain health. Get the pre-order perks here: https://lnkd.in/grFs4K46 #guthealth #mentalhealth #KineonHEAL #KineonCALM #KineonHealPlus #KineonCalmPlus #vagusnerve #guthealthmanagement #ibs #gutissues #colitis #ibstreatment #colitistreatment #gutbrainconnection #secondbrain #gutpain #gutinflammation #anxietytreatment #depressiontreatment #insomniatreatment #gutbrainaxis #paintopossible #Vagusnervestimulation #treatanxiety #treatdepression #stressmanagement

💥Big News: FDA Clears Neuralace Medical’s Axon Therapy for PDN I'm thrilled to share that as an investor in Neuralace Medical, I’m part of a major breakthrough in pain management. Neuralace's innovative Axon Therapy, using non-invasive mPNS, has just received FDA clearance for treating a second indication - Painful Diabetic Neuropathy (PDN). ➡️This is huge for millions suffering from PDN. Why? Painful Diabetic Neuropathy (PDN) is difficult to treat because it involves complex nerve damage caused by diabetes, which leads to a range of symptoms like burning or numbness. These symptoms vary greatly between individuals, and they often don’t respond well to standard pain medications. Additionally, the progressive nature of PDN and its impact on mental health make treatment and management challenging. 💡Axon Therapy treatment is quick, painless, and highly effective, showing remarkable results in clinical trials. ➡️It’s not just about pain relief; it’s about improving patients’ quality of life. Proud to support Neuralace’s commitment to non-invasive, non-opioid, patient-centered care. This marks a significant step in our journey to revolutionize neuropathic pain treatment. ➡️Learn more at neuralacemedical.com. NuFund Venture Group MooDoos Investments FusionX Ventures Mesa Verde Venture Partners Jeffrey Friedman #healthcareinnovation #neuralacemedical #painmanagement #PDNTreatment #FDAApproval #opioidcrisis #opioidfree

Today marks the first Eterna™ SCS System implanted in Australia, offering patients the latest spinal cord stimulator (SCS) from Abbott | Neuromodulation. The procedure was performed by Dr. James Yu.   Find out more about this new system that harnesses low-energy BurstDR™ stimulation and is clinically proven(1) to reduce pain at https://Eterna.Abbott/EMEA   #AbbottProud Important Safety Info: https://bit.ly/isi_int   *BurstDR™ stimulation superiority when compared to traditional tonic SCS stimulation. 1. Deer T, Slavin KV, Amirdelfan K, et al. Success using neuromodulation with BURST (SUNBURST) study: results from a prospective, randomized controlled trial using a novel burst waveform. Neuromodulation. 2018;21(1):56-66. doi:10.1111/ner.12698

🔹One more opportunity to raise awareness about #neuromodulation! 🔹Help International Neuromodulation Society spread the word! 🔹Therapies such as #SpinalCordStimulation (#SCS), #targeteddrugdelivery (#TDD, #IDDS, #intrathecal therapy), #radiofrequencyablation or #restorativeneurostimulation (stimulation of #multifidus) can be transformative therapies changing patients‘ lives!